**ARHGEF9** gene variant leads to developmental and epileptic encephalopathy: Genotypic phenotype analysis and treatment exploration

**Haiyan Yang** | **Hongmei Liao** | **Siyi Gan** | **Ting Xiao** | **Liwen Wu**

1Department of Neurology, Hunan Children’s Hospital, Changsha, P.R. China
2Department of Pediatrics, Xiangya Hospital, Central South University, Changsha, P.R. China

**Correspondence**
Liwen Wu, Department of Neurology, Hunan Children’s Hospital, Ziyuan Road 86th, Changsha 410007, Hunan, P.R. China.
Email: 271417152@qq.com

**Funding information**
Huxiang Youth Talent Support Program, Grant/Award Number: 2021RC3117; National Natural Science Foundation of China, Grant/Award Number: 82171453 and 81671297; Natural Science Foundation of Hunan Province, Grant/Award Number: 2021JJ30393

**Abstract**

**Background:** The **ARHGEF9** gene variants have phenotypic heterogeneity, the number of reported clinical cases are limited and the genotype–phenotype relationship is still unpredictable.

**Methods:** Clinical data of the patients and their family members were gathered in a retrospective study. The exome sequencing that was performed on peripheral blood samples was applied for genetic analysis. We used the **ARHGEF9** gene as a key word to search the PubMed database for cases of **ARHGEF9** gene variants that have previously been reported and summarized the reported **ARHGEF9** gene variant sites, their corresponding clinical phenotypes, and effective treatment.

**Results:** We described five patients with developmental and epileptic encephalopathy caused by **ARHGEF9** gene variants. Among them, the antiepileptic treatment of valproic acid and levetiracetam was effective in two cases individually. The exome sequencing results showed five children with point mutations in the **ARHGEF9** gene: p.R365H, p.M388V, p.D213E, and p.R63H. So far, a total of 40 children with **ARHGEF9** gene variants have been reported. Their main clinical phenotypes include developmental delay, epilepsy, epileptic encephalopathy, and autism spectrum disorders. The variants reported in the literature, including 22 de novo variants, nine maternal variants, and one unknown variant. There were 20 variants associated with epileptic phenotypes, of which six variants are effective for valproic acid treatment.

**Conclusion:** The genotypes and phenotypes of **ARHGEF9** gene variants represent a wide spectrum, and the clinical phenotype of epilepsy is often refractory and the prognosis is poor. The p.R365H, p.M388V, p.D213E, and p.R63H variants have not been reported in the current literature, and our study has expanded the genotype spectrum of **ARHGEF9** gene. Our findings indicate that levetiracetam and valproic acid can effectively control seizures in children with epileptic phenotype caused by **ARHGEF9** gene variations. These findings will help clinicians improve the level of diagnosis and treatment of the genetic disease.
1 | BACKGROUND

The ARHGEF9 gene (OMIM: 300429) encodes collybitin, which belongs to the Rho-like GTPases family, which acts as a molecular switch by cycling from an active GTP-bound state to an inactive GTP-bound state, playing a pivotal role in the formation of postsynaptic glycine and inhibitory gamma-aminobutyric acid receptor clusters and is involved in the regulation of neural excitability and the pathogenesis of epilepsy (Scala, Nishikawa, et al., 2021; Shimojima et al., 2011). ARHGEF9 gene is associated with an X-linked developmental-epileptic encephalopathy and extensive clinical phenotype, including hyperactivity; impulsivity, hypotonia, and autism spectrum disorder (Alber et al., 2017; Harvey et al., 2004). The ARHGEF9 gene has obvious clinical heterogeneity, and the relationship between its genotype and clinical phenotype is still unclear, and there is a lack of systematic research. Here, we report five patients with developmental and epileptic encephalopathy caused by ARHGEF9 gene variant, and summarize the previously reported literature on ARHGEF9 gene, analyze their genotypes and phenotypes, and explore potentially effective treatments.

2 | METHODS

2.1 | Patient

Five patients were included in the study. The patients were managed at the Department of Neurology, Hunan Children’s Hospital. The parents of the patients provided written informed consent.

2.2 | Exome sequencing of peripheral blood

The exome sequencing method was performed according to our previous research methods (Yang et al., 2020). In brief, genomic DNA was fragmented into ~200 bp and captured by gene panel target capture kit, then DNA library was sequenced on Illumina platform. After removing adapters and low quality reads, paired-End clean reads were mapped to the human reference genome (GRCh37/hg19) by BWA. Sequence variants were annotated using population and literature databases, including 1000 Genomes, dbSNP, GnomAD, Clinvar, HGMD, and OMIM. Variant interpretation was performed according to the American College of Medical Genetics (ACMG) guidelines (Richards et al., 2015). The exome sequencing was performed simultaneously on samples from the patients and their parents.

2.3 | Literature review

We used the ARHGEF9 gene as a key word to search the PubMed database for cases of ARHGEF9 gene variants that have previously been reported and summarized the reported ARHGEF9 gene variants, their corresponding clinical phenotypes and effective treatment.

3 | RESULTS

3.1 | Case report

Case 1 was a 4-year-old male child who presented with recurrent seizures at the age 2 months. The seizure types were generalized tonic–clonic seizure and thermosensitive epilepsy. The electroencephalogram (EEG) showed normal background, widespread spikes, and spikes slow waves. The Gesell child development scale showed severe developmental delay. According to the child’s clinical manifestations and EEG characteristics, the child was diagnosed with developmental and epileptic encephalopathy. After the diagnosis of developmental and epileptic encephalopathy was confirmed, the child was treated with valproic acid for antiepileptic treatment. The child’s seizures were gradually controlled. At present, the child has no seizures, but still has severe developmental delay, which is characterized by being unable to walk independently at the age of 4 years.

Case 2 was a 10-year-old male child who presented with recurrent seizures and hyperarousal to noise at the age of 6 months. The seizure types were generalized tonic–clonic seizure, myoclonus, seizure status, and thermosensitive epilepsy. The electroencephalogram (EEG) showed normal background, widespread spikes, and spikes slow waves. The Gesell child development scale showed severe developmental delay. According to the child’s clinical manifestations and EEG characteristics, the child was diagnosed with developmental and epileptic encephalopathy. After the diagnosis of developmental and epileptic encephalopathy was confirmed, the child was treated with valproic acid for antiepileptic treatment. The child’s seizures were gradually controlled. At present, the child has no seizures, but still has severe developmental delay, which is characterized by being unable to walk independently at the age of 4 years.

Key words

ARHGEF9 gene, child, developmental delay, epilepsy, treatment
topiramate, oxcarbazepine, and ketogenic diet for antiepileptic treatment successively, and the control of seizures was ineffective. At present, the child still has generalized tonic–clonic seizure and severe developmental delay, which is manifested as that he still cannot walk independently and cannot speak at the age of 10 years.

Case 3 was a 3 years and 7 months old male child who presented with recurrent febrile seizures at the age of 1 year and 4 months. After 2-year-old, the patient presented with nonfebrile seizures, and the seizure types included generalized tonic–clonic seizure, myoclonus, autonomic seizure, seizure status, and thermosensitive epilepsy. The EEG revealed slow wave background, widespread spikes, spikes slow waves, obvious in frontal area. The Gesell child development scale showed severe developmental delay. According to the child’s clinical manifestations and EEG characteristics, the child was eventually diagnosed with developmental and epileptic encephalopathy. After the diagnosis of developmental and epileptic encephalopathy was confirmed, the child was treated with levetiracetam for antiepileptic treatment. The child’s seizures were gradually controlled. At present, the child has no seizures, but has severe developmental delay, which is manifested as that he can only speak at the age of 2 years and 3 months, and still cannot walk independently at the age of 3 years and 7 months.

Case 4 was a 2 years and 9 months old male child who presented with recurrent seizures at the age 6 months. The seizure types included focal secondary generalized tonic–clonic seizure and cluster seizures. The EEG revealed that normal background, spikes waves, spikes slow waves in bilateral occipital area during sleep. The Gesell child development scale showed developmental delay. According to the child’s clinical manifestations and EEG characteristics, the child was eventually diagnosed with developmental and epileptic encephalopathy. After the diagnosis of developmental and epileptic encephalopathy was confirmed, the child was treated with levetiracetam for antiepileptic treatment. The child’s seizures were gradually controlled. At present, the child has no seizures but has moderate developmental delay, which is manifested as that he can walk independently at the age of 2 years, and only speak at the age of 2 years and 4 months.

Case 5 was a 2 years and 4 months old male child who presented recurrent seizures at the age 11 months. The seizure types included focal secondary generalized tonic–clonic seizure and thermosensitive epilepsy. The EEG showed slow wave background, spikes waves, spikes slow waves in occipital and posterior temporal area. The Gesell child development scale showed mild developmental delay. According to the child’s clinical manifestations and EEG characteristics, the child was diagnosed with developmental and epileptic encephalopathy. After the diagnosis of epilepsy was confirmed, the child was treated with valproic acid for antiepileptic treatment. The child’s seizures were gradually controlled. At present, the child has no seizures, but still has mild developmental delay, which is characterized by being able to walk independently at the age of 1 years and 3 months, and being unable to speak at the age of 2 years and 4 months. See Table 1 for details.

### 3.2 Genetic evaluation

The onset age of epilepsy in the five children was infantile, considering the possibility of genetic etiology, and the exome sequencing was performed for family verification in their peripheral blood. Case 1 had an *ARHGEF9* c.1094G>A (p.R365H) hemizygous variant, which was inherited from the mother. According to the ACMG variation classification guidelines, this variation was analyzed as likely pathogenic. Case 2 had *ARHGEF9* c.1162A>G (p.M388V) homozygous variant which was inherited from the mother. According to the ACMG variation classification guidelines, this variation was analyzed as variant of uncertain significance (VUS). In addition, case 2 was also combined with *SCN1A* c.4261A>G (p.K1421E) heterozygous variant, the sequencing data showed that his parents did not carry the variant, which could be a de novo variant. According to the ACMG variation classification guidelines, this variation was analyzed as likely pathogenic. Case 3 had an *ARHGEF9* c.639C>G (p.D213E) hemizygous variant, which was inherited from the mother. According to the ACMG variation classification guidelines, this variation was analyzed as variant of uncertain significance (VUS). In addition, case 2 was also combined with *SCN1A* c.4261A>G (p.K1421E) heterozygous variant, the sequencing data showed that his parents did not carry the variant, which could be a de novo variant. According to the ACMG variation classification guidelines, this variation was analyzed as likely pathogenic. Case 5 had an *ARHGEF9* c.1094G>A (p.R365H) hemizygous variant, the sequencing data showed that his parents did not carry the variant, which could be a de novo variant. According to the ACMG variation classification guidelines, this variation was analyzed as likely pathogenic. See Table 1 for details.

### 3.3 Summary of the reported *ARHGEF9* cases

So far, a total of 40 children with *ARHGEF9* gene variants have been reported (Table 2). Their clinical phenotypes include developmental delay, epilepsy, brain atrophy in the cerebral cortex and cerebellar vermis, hyperarousal to noise, hyperactivity, impulsivity, shyness, motor incoordination,
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 |
|-----------|-----------|-----------|-----------|-----------|
| **Sex**   | M         | M         | M         | M         |
| **Age**   | 4 y       | 10 y      | 3 y 7 m   | 2 y 9 m   | 2 y 4 m   |
| **Clinical feature** | Epilepsy; severe developmental delay | Epilepsy; hyperarousal to noise; severe developmental delay | Recurrent febrile seizures; epilepsy; severe developmental delay | Epilepsy; moderate developmental delay | Epilepsy; mild developmental delay |
| **Seizure types** | Generalized tonic–clonic seizure; thermosensitive epilepsy | Generalized tonic–clonic seizure; myoclonus; seizure status; thermosensitive epilepsy | Generalized tonic–clonic seizure; myoclonus; autonomic seizure; seizure status; thermosensitive epilepsy | Focal secondary generalized tonic–clonic seizure; cluster seizures | Focal secondary generalized tonic–clonic seizure; thermosensitive epilepsy |
| **EEG**   | Normal background, widespread spikes, spikes slow waves | Slow wave background, widespread spikes, spikes slow waves | Slow wave background, widespread spikes, spikes slow waves, obvious in frontal area | Normal background, spikes waves, spikes slow waves in bilateral occipital area during sleep | Slow wave background, spikes waves, spikes slow waves in occipital, and posterior temporal area |
| **Mutation** | *ARHGEF9*: NM_015185.2:exon8: c.1094G>A (p.R365H) | *ARHGEF9*: NM_015185.2:exon8: c.1162A>G (p.M388V) | *SCN1A*: NM_006920: exon22: c.4261A>G (p.K1421E) | *ARHGEF9*: NM_00117347.1:exon5: c.639C>G (p.D213E) | *ARHGEF9*: NM_00117347.1:exon8: c.1094G>A (p.R365H) |
| **Inheritance** | Maternal | Maternal; de novo | Maternal | De novo | De novo |
| **SIFT**  | Damaging; 0.001 | Tolerated; 1 | Damaging; 0.04 | Damaging; 0.001 | Damaging; 0.001 |
| **LRT**   | Deleterious; 0 | Deleterious; 0 | Deleterious; 0 | Deleterious; 0 | Deleterious; 0 |
| **PhyloP100way** (conservation score) | 7.376 | 3.722 | 2.535 | 7.161 | 7.376 |
| **ACMG classification** | LP | VUS; LP | VUS | LP | LP |
| **Effective treatment** | Valproic | Refractory | Levetiracetam | Levetiracetam | Valproic |
| **Outcome** | Seizure free; severe developmental delay | Seizure ineffective; severe developmental delay | Seizure free; severe developmental delay | Seizure free; moderate developmental delay | Seizure free; mild developmental delay |

**Abbreviations:** ACMG, American College of Medical Genetics; F, female; LP, likely pathogenic; LRT, likelihood ratio test; MRI, magnetic resonance imaging; M, male; N/A, not available; P, pathogenic; SIFT, sorting intolerant from tolerant; VUS, variant of unknown significance; y, year.
| Reference                  | Mutation                        | Case (n) | Inheritance (n) | Sex (n) | Age (m) | Clinical feature                                                                 | Effective treatment |
|----------------------------|---------------------------------|----------|-----------------|---------|---------|---------------------------------------------------------------------------------|---------------------|
| Harvey et al. (2004)       | p.G55A                          | 1        | De novo         | Male (1)| Died at age 4.4 y | Developmental delay; epilepsy; brain atrophy in the cerebral cortex and cerebellar vermis; hyperarousal to noise | Refractory          |
| Marco et al. (2008)        | 46,X.inv(X)(q11.1q27.3)         | 1        | N/A             | Female (1) | 15 y | Developmental delay; hyperactivity; impulsivity, shyness; motor incoordination | N/A                 |
| Alber et al. (2017)        | 46,X,t(X;20)(q12;p13)           | 1        | De novo (1)     | Female (1) | 10 y | Severe intellectual disability; autistic features; hyperactivity; epilepsy       | CBZ, PB, TPM, LEV, OXC |
| Alber et al. (2017)        | 46,X,t(X;18)(q11.1;q11.21)      | 1        | De novo (1)     | Female (1) | 15 y | Severe intellectual disability; hyperactivity; epilepsy                          | VPA                 |
| Alber et al. (2017)        | Xq11.1 deletion: arrXq11.1(62838630-62865334) | 1        | De novo (1)     | Female (1) | 9 y | Moderate intellectual disability; hyperactivity; hypotonia                      | N/A                 |
| Alber et al. (2017)        | Xq11.1 deletion: arrXq11.1(62854862-62862403) | 1        | De novo (1)     | Female (1) | 4 y | Moderate intellectual disability; epilepsy                                        | Refractory          |
| Alber et al. (2017)        | Xq11.1 deletion: arrXq11.1(61848414-63138698) | 1        | De novo (1)     | Male (1) | 11 y | Severe intellectual disability; hyperactivity; epilepsy                          | CBZ, PB, TPM, LEV, OXC |
| Alber et al. (2017)        | Xq11.1 deletion: arrXq11.1(62321746-63058548) | 1        | De novo (1)     | Male (1) | 5 y | Severe intellectual disability; epilepsy                                          | VPA                 |
| Alber et al. (2017)        | p.Q2a                            | 1        | Maternal (1)    | Male (1) | 5 y | Severe intellectual disability; epilepsy                                           | Refractory          |
| Alber et al. (2017)        | p.S317W                          | 2        | Maternal (2)    | Male (2) | 27 y | Severe intellectual disability; epilepsy                                          | CBZ, CLB            |
| Alber et al. (2017)        | p.L177P                          | 1        | De novo (1)     | Male (1) | 4 y | Severe intellectual disability; epilepsy; autistic features                      | VPA, LEV, LTG       |
| Alber et al. (2017)        | p.R104Q                          | 1        | De novo (1)     | Male (1) | 15 y | Severe intellectual disability; epilepsy; autistic features; hyperactivity       | Refractory          |
| Alber et al. (2017)        | p.R290H                          | 1        | De novo (1)     | Male (1) | 57 y | Moderate intellectual disability; epilepsy                                        | Refractory          |
| Alber et al. (2017)        | p.R338W                          | 1        | Maternal (1)    | Male (1) | 26 y | Moderate intellectual disability; epilepsy                                        | N/A                 |
| Alber et al. (2017)        | p.E400K                          | 1        | De novo (1)     | Male (1) | 2 y | Moderate intellectual disability                                                  | N/A                 |
| Alber et al. (2017)        | p. ? Exon skipping               | 1        | De novo (1)     | Male (1) | 3 y | Moderate intellectual disability                                                  | N/A                 |
| Alber et al. (2017)        | p.R356Q                          | 1        | Maternal (1)    | Male (1) | 28 y | Mild intellectual disability                                                     | N/A                 |
| Marco et al. (2008)        | 46,X.inv(X)(q11.1q27.3)          | 1        | De novo (1)     | Female (1) | 15 y | Moderate intellectual disability; hyperekplexia                                  | N/A                 |

(Continues)
| Reference       | Mutation                                      | Case (n) | Inheritance (n) | Sex (n) | Age (m) | Clinical feature                                      | Effective treatment |
|-----------------|-----------------------------------------------|----------|-----------------|---------|---------|------------------------------------------------------|---------------------|
| Wang et al. (2018) | p.R290C                                       | 4        | De novo (4)     | Male (4)| 10 y    | Intellectual disability; epileptic encephalopathy   | Refractory          |
| Aarabi et al. (2019) | Xq11.11deletion:arrXq11.1| 2        | De novo (2)     | Female (2)| 23 y    | Autism spectrum disorders; developmental delay       | N/A                 |
| Yao et al. (2020) | c.381+3A>G                                    | 1        | Maternal (1)    | Male (1)| 1.8 y   | Developmental delay and epilepsy                     | N/A                 |
| Yao et al. (2020) | p.I294T                                       | 1        | Maternal (1)    | Male (1)| 15 y    | Developmental delay and epilepsy                     | N/A                 |
| Yao et al. (2020) | p.R357I                                       | 1        | Maternal (1)    | Male (1)| 8 y     | Developmental delay and epilepsy                     | N/A                 |
| Scala et al. (2020) | p.R104Q                                       | 1        | De novo (1)     | Female (1)| 5 y     | Severe intellectual disability; epilepsy; hypotonia; dysmorphic features; corpus callosum hypoplasia | OXC, VPA            |
| Scala et al. (2021) | p.E179K                                       | 1        | De novo (1)     | Female (1)| 25 y    | Moderate intellectual disability; hypotonia; dysmorphism; autism spectrum disorders; psychotic episode | N/A                 |
| Lesca et al. (2011) | Xq11.11deletion:arrXq11.1| 1        | De novo (1)     | Male (1)| 6 y     | Developmental delay; epilepsy, macrosomia; dysmorphic features | OXC, LEV            |
| Freri et al. (2020) | p.G496L                                       | 1        | De novo (1)     | Male (1)| 16 y    | Epilepsy; intellectual disability                   | Refractory          |
| Shimojima et al. (2011) | Xq11.11deletion:arrXq11.1| 1        | De novo (1)     | Male (1)| 5 y     | Developmental delay; epilepsy                        | VPA                 |
| Shimojima et al. (2011) | p.Q2X                                         | 1        | Maternal (1)    | Male (1)| 5.5 y   | Developmental delay; epilepsy                        | Refractory          |
| Klein et al. (2017) | p.G323R                                       | 4        | Maternal        | Male (4)| 21 y    | Intellectual disability; focal epilepsy; febrile seizures | VPA, CBZ, perampanel |
| Bhat et al. (2016) | Xq11.1-Xq11.2 deletion:arrXq11.1-Xq11.2| 1        | De novo (1)     | Female (1)| 8 y     | Autism spectrum disorder                             | N/A                 |

Abbreviations: a, lifted over from Hg18 to Hg19; CBZ, carbamazepine; CLB, clobazam; LEV, levetiracetam; LTG, lamotrigine; m, median; n, number; N/A, not available; OXC, oxcarbazepine; PB, phenobarbital; TPM, topiramate; VPA, valproic acid; y, year.
autistic features, hypotonia, hyperekplexia, epileptic encephalopathy, autism spectrum disorders, dysmorphic features; corpus callosum hypoplasia, dysmorphism, psychotic episode, macrosomia, and febrile seizures (Aarabi et al., 2019; Alber et al., 2017; Bhat et al., 2016; Freri et al., 2020; Kalscheuer et al., 2009; Klein et al., 2017; Lesca et al., 2011; Marco et al., 2008; Scala, Zonneveld-Huijssoon, et al., 2021; Striano & Zara, 2017; Wang et al., 2018; Yao et al., 2020). The variants reported in the literature (Aarabi et al., 2019; Alber et al., 2017; Bhat et al., 2016; Freri et al., 2020; Kalscheuer et al., 2009; Klein et al., 2017; Lesca et al., 2011; Marco et al., 2008; Scala, Zonneveld-Huijssoon, et al., 2021; Striano & Zara, 2017; Wang et al., 2018; Yao et al., 2020), including 22 de novo variants, nine maternal variants, and one unknown variant. There were 20 variants effective for valproic acid treatment. There were three variants associated with autism spectrum disorders, see Table 2 for details. The novel and previously reported ARHGEF9 single nucleotide variants are shown in Figure 1.

### 4 | DISCUSSION

On the one hand, with the development and widespread application of genomics, more and more genetic diseases have been diagnosed early. On the other hand, more and more genes are found to have clinical heterogeneity and lack of specific genotype–phenotype correlations, making accurate diagnosis of the disease challenging (Scala et al., 2020; Wang et al., 2018). Therefore, this study summarizes and analyzes the clinical phenotype and genotype of the ARHGEF9 gene with strong clinical heterogeneity, with the hope that clinicians will improve the understanding of the disease and its early diagnosis and improve the prognosis of the disease, which has important clinical significance. The ARHGEF9 gene is a gene with strong clinical heterogeneity, and different variants correspond to different clinical phenotypes (Wang et al., 2018). According to current literature reports, the main clinical manifestations reported for ARHGEF9 gene variants are epilepsy, developmental delay, intellectual disability, hyperarousal to noise, hyperactivity, and autism spectrum disorders (Aarabi et al., 2019; Alber et al., 2017; Bhat et al., 2016; Freri et al., 2020; Kalscheuer et al., 2009; Klein et al., 2017; Lesca et al., 2011; Marco et al., 2008; Scala, Zonneveld-Huijssoon, et al., 2021; Striano & Zara, 2017; Wang et al., 2018; Yao et al., 2020). The seizure types reported in previous literature included focal seizures and generalized tonic–clonic seizures. In this study, five children with ARHGEF9 gene variant were reported, all of whom were male, and their clinical manifestations included developmental and epileptic encephalopathy and febrile seizures, the types of seizures included focal seizures, generalized tonic–clonic seizures, myoclonus, and thermosensitive epilepsy which were consistent with the clinical phenotypes of children with ARHGEF9 gene variant reported in previous literatures.

The ARHGEF9 gene variants reported in the literature include chromosomal variants and point mutations, among which chromosomal variants include chromosomal translocations, insertions, and deletions (Aarabi et al., 2019; Alber et al., 2017; Bhat et al., 2016; Freri et al., 2020; Kalscheuer et al., 2009; Klein et al., 2017; Lesca et al., 2011; Marco et al., 2008; Scala, Zonneveld-Huijssoon, et al., 2021; Striano & Zara, 2017; Wang et al., 2018; Yao et al., 2020). The inheritance of this gene variation has been reported in the current literature as maternal and de novo inheritance (Alber et al., 2017). Our review revealed that the ARHGEF9 disease was not uniform and varies with the gene variant and likely other genetic and extragenetic factors. Therefore, the diagnostic approach in candidate patients still requires chromosomal microarray testing as the first-line genetic testing because of the substantial diagnostic yield and low relative cost, followed by a gene panel or exome sequencing approach as second tier. There are differences in clinical manifestations caused by different variants of this gene. Among the ARHGEF9 gene variants reported in the literature, 20 showed epilepsy clinical phenotypes (Alber et al., 2017; Freri et al., 2020; Harvey et al., 2004; Klein et al., 2017; Lesca et al., 2011; Scala, Zonneveld-Huijssoon, et al., 2021;
Shimojima et al., 2011; Wang et al., 2018; Yao et al., 2020), and three showed autism spectrum clinical phenotypes (Aarabi et al., 2019; Bhat et al., 2016; Scala, Zonneveld-Huijssoon, et al., 2021). The details of the variants are shown in Table 2. In this study, we reported five children with ARHGEF9 variants presenting with epileptic encephalopathy. They were p.R365H, p.M388V, p.D213E, and p.R63H, of which two children had variants at the same gene site, one of which was maternal inheritance and the other was de novo variant. Considering that the genetic mode of this gene is XR, it is possible that there may be maternal inheritance or de novo variant in different patients at the same gene site. All of them have not been reported in the current literature, and our study has expanded the genotype spectrum of ARHGEF9 gene.

Epilepsy is a very common clinical phenotype of ARHGEF9 gene variants (Alber et al., 2017; Freri et al., 2020; Harvey et al., 2004; Klein et al., 2017; Lesca et al., 2011; Scala, Zonneveld-Huijssoon, et al., 2021; Shimojima et al., 2011; Wang et al., 2018; Yao et al., 2020). Antiepileptic drugs are the first choice for the treatment of epilepsy (Harvey et al., 2004). At present, the pathogenesis of epilepsy phenotype caused by ARHGEF9 gene variations is still unclear. Our review showed that ARHGEF9 gene variations caused seizures were often difficult to control, and antiepileptic drugs were not effective, which often required combined treatment with several antiepileptic drugs, with poor prognosis and often left behind varying degrees of developmental delay (Harvey et al., 2004). Among the five children in our study, the antiepileptic treatment of valproic acid was effective in two cases, and the antiepileptic treatment of levetiracetam was effective in two cases, and the seizures were controlled. At present, none of the four children had recurrent seizures. Analysis of the effective reason for seizures control in children may be that the ARHGEF9 coding protein collybistin plays a key role in the formation of postsynaptic glycine and inhibitory γ-aminobutyric acid receptor clusters. Disruption of collybistin results in an imbalance of inhibitory and excitatory neurotransmitters (Neuray et al., 2020). Valproic acid can lead to the increase of γ-aminobutyric acid level in vivo, and both levetiracetam and valproic acid can inhibit neuronal excitability. Further confirmation requires animal and cellular functional studies. One child was successively given levetiracetam, topiramate, oxazepine, and ketogenic diet in combination with antiepileptic treatment, but the seizures of the child were still not controlled. In this case, the child had ARHGEF9 c.1162A>G (p.M388V) homozygous variant, which was analyzed as variant of VUS by the ACMG variation classification guidelines. Although the pathogenicity of ARHGEF9 c.1162A>G (p.M388V) is defined as VUS, but there is a lack of relevant literature reports at present. With more and more literature reports in the future, the pathogenicity rating may also be reevaluated. So we still believe that the SCN1A and ARHGEF9 variants have a synergistic effect on clinical phenotypes in the child.

In conclusion, the genotypes and phenotypes of ARHGEF9 gene variants represent a wide spectrum, and the clinical phenotype of epilepsy is often refractory and the prognosis is poor. The p.R365H, p.M388V, p.D213E, and p.R63H variants have not been reported in the current literature, and our study has expanded the genotype spectrum of ARHGEF9 gene. Our findings indicate that levetiracetam and valproic acid can effectively control seizures in children with epileptic phenotype caused by ARHGEF9 gene variations. These findings will help clinicians improve the level of diagnosis and treatment of the genetic disease, use effective antiepileptic drugs as soon as possible to control seizures, and help improve the prognosis of children.

ACKNOWLEDGMENTS
The authors wish to thank the patients and their families for their participation in this study.

CONFLICT OF INTEREST
The authors declare that they have no competing interests.

AUTHOR CONTRIBUTIONS
HY conducted the literature review and drafted the manuscript. HL, SG and TX made substantial contributions to the conception and interpretation of data. LW were responsible for revising the manuscript critically and gave final approval of the version to be published. All authors read and approved the manuscript.

DATA AVAILABILITY STATEMENT
The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

ETHICAL COMPLIANCE
This study was approved by the Medical Ethics Committee of Hunan Children’s Hospital.

ORCID
Haiyan Yang https://orcid.org/0000-0003-1164-8788
REFERENCES

Aarabi, M., Kessler, E., Madan-Khetarpal, S., Surti, U., Bellissimo, D., Rajkovic, A., & Yatsenko, S. A. (2019). Autism spectrum disorder in females with ARHGEF9 alterations and a random pattern of X chromosome inactivation. European Journal of Medical Genetics, 62(4), 239–242.

Alber, M., Kalscheuer, V. M., Marco, E., Sherr, E., Lesca, G., Till, M., Gradek, G., Wiesener, A., Korenke, C., Mercier, S., Becker, F., Yamamoto, T., Scherer, S. W., Marshall, C. R., Walker, S., Dutta, U. R., Dalal, A. B., Suckow, V., Jamali, P., ... Minassian, B. A. (2017). ARHGEF9 disease: Phenotype clarification and genotype-phenotype correlation. Neurology Genetics, 3(3), e148.

Bhat, G., LaGrave, D., Millson, A., Herriges, J., Lamb, A. N., & Matalon, R. (2016). Xq11.1-11.2 deletion involving ARHGEF9 in a girl with autism spectrum disorder. European Journal of Medical Genetics, 59(9), 470–473.

Freri, E., Castellotti, B., Didato, G., DiFrancesco, J. C., & Granata, T. (2020). Epilepsy and NREM-parasomnia caused by novel hemizygous ARHGEF9 mutation. Sleep Medicine, 76, 158–159.

Harvey, K., Duguid, I. C., Allred, M. J., Beatty, S. E., Ward, H., Keep, N. H., Lingenfelter, S. E., Pearce, R. B., Lundgren, J., Owen, M. J., Smart, T. G., Lüscher, B., Rees, M. I., & Harvey, R. J. (2004). The GDP-GTP exchange factor collybistin: an essential determinant of neuronal gephyrin clustering. The Journal of Neuroscience, 24(25), 5816–5826.

Kalscheuer, V. M., Musante, L., Fang, C., Hoffmann, K., Puch, C., Carta, E., Deas, E., Venkateswarlu, K., Menzel, C., Ullmann, R., Tommerup, N., Dalprà, L., Tzschach, A., Selicorni, A., Lüscher, B., Ropers, H. H., Harvey, K., & Harvey, R. J. (2009). A balanced chromosomal translocation disrupting ARHGEF9 is associated with epilepsy, anxiety, aggression, and mental retardation. Human Mutation, 30(1), 61–68.

Klein, K. M., Pendziwiat, M., Eilam, A., Gilad, R., Blatt, I., Rosenow, F., Kanaan, M., Helbig, I., Afawi, Z., & Israeli-Palestinian Epilepsy Family Consortium. (2017). The phenotypic spectrum of ARHGEF9 includes intellectual disability, focal epilepsy and febrile seizures. Journal of Neurology, 264(7), 1421–1425.

Lesca, G., Till, M., Labalme, A., Valler, D., Hugoneng, C., Philip, N., Edery, P., & Sanlaville, D. (2011). De novo Xq11.11 microdeletion including ARHGEF9 in a boy with mental retardation, epilepsy, macrocephaly, and dysmorphic features. American Journal of Medical Genetics. Part A, 155A(7), 1706–1711.

Marco, E. J., Abidi, F. E., Bristow, J., Dean, W. B., Cotter, P., Jeremy, R. J., Schwartz, C. E., & Sherr, E. H. (2008). ARHGEF9 disruption in a female patient is associated with X linked mental retardation and sensory hyperarousal. Journal of Medical Genetics, 45(2), 100–105.

Neuray, C., Maroofian, R., Scala, M., Sutton, T., Pai, G. S., Mojarrad, M., Khashab, H. E., deHoll, L., Yue, W., Alsaid, H. S., Zanetti, M. N., Bello, O., Person, R., Eslahi, A., Khazaie, Z., Feizabadi, M. H., Efthymiou, S., SYNaPS Study Group, Groppa, S., ... Houlden, H. (2020). Early-infantile onset epilepsy and developmental delay caused by bi-allelic GAD1 variants. Brain, 143(8), 2388–2397.

Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., Voelkerding, K., Rehm, H. L., & ACMG Laboratory Quality Assurance Committee. (2015). Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine, 17(5), 405–424.

Scala, M., Bianchi, A., Bisulli, F., Coppola, A., Elia, M., Trivisano, M., Pruna, D., Pippucci, T., Canafoglia, L., Lattanzi, S., Franceschetti, S., Nobile, C., Gambardella, A., Michelucci, R., Zara, F., & Striano, P. (2020). Advances in genetic testing and optimization of clinical management in children and adults with epilepsy. Expert Review of Neurotherapeutics, 20(3), 251–269.

Scala, M., Nishikawa, M., Nagata, K. I., & Striano, P. (2021). Pathophysiological mechanisms in neurodevelopmental disorders caused by Rac GTPases dysregulation: what's behind neuro-RACopathies. Cell, 10(12), 3395.

Scala, M., Zonneveld-Huijssoon, E., Brienza, M., Mecarelli, O., van der Hout, A. H., Zambrelli, E., Turner, K., Zara, F., Peron, A., Vignoli, A., & Striano, P. (2021). De novo ARHGEF9 missense variants associated with neurodevelopmental disorder in females: expanding the genotypic and phenotypic spectrum of ARHGEF9 disease in females. Neurogenetics, 22(1), 87–94.

Shimojima, K., Sugawara, M., Shichiji, M., Mukaida, S., Takayama, R., Imai, K., & Yamamoto, T. (2011). Loss-of-function mutation of collybistin is responsible for X-linked mental retardation associated with epilepsy. Journal of Human Genetics, 56(8), 561–565.

Striano, P., & Zara, F. (2017). ARHGEF9 mutations cause a specific recognizable X-linked intellectual disability syndrome. Neurology Genetics, 3(3), e159.

Wang, J. Y., Zhou, P., Wang, J., Tang, B., Su, T., Liu, X. R., Li, B. M., Meng, H., Shi, Y. W., Yi, Y. H., He, N., & Liao, W. P. (2018). ARHGEF9 mutations in epileptic encephalopathy/intellectual disability: toward understanding the mechanism underlying phenotypic variation. Neurogenetics, 19(1), 9–16.

Yang, H., Yin, F., Gan, S., Pan, Z., Xiao, T., Kessi, M., Yang, Z., Zhang, V. W., & Wu, L. (2020). The study of genetic susceptibility and mitochondrial dysfunction in mesial temporal lobe epilepsy. Molecular Neurobiology, 57(9), 3920–3930.

Yao, R., Zhang, Y., Liu, J., Wang, J., Xu, Y., Li, N., Wang, J., & Yu, T. (2020). Clinical and molecular characterization of three novel ARHGEF9 mutations in patients with developmental delay and epilepsy. Journal of Molecular Neuroscience, 70(6), 908–915.

How to cite this article: Yang, H., Liao, H., Gan, S., Xiao, T. & Wu, L. (2022). ARHGEF9 gene variant leads to developmental and epileptic encephalopathy: Genotypic phenotype analysis and treatment exploration. Molecular Genetics & Genomic Medicine, 10, e1967. https://doi.org/10.1002/mgg3.1967